Figure 3

Recurrence-free survival for oestrogen receptor-positive patients with low/normal (<2.3) and increased (>2.3) expression of 17β-hydroxysteroid dehydrogenase (HSD) type 1 mRNA (n=135 and n=44, respectively). The entire follow-up period is shown in (A). Patients still recurrence-free after 5 years were analysed for later events and their outcome is shown in (B).